SYNTA PHARMACEUTICALS
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune disea... ses. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.
SYNTA PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2000-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.syntapharma.com
Total Employee:
51+
Status:
Closed
Contact:
(781) 274-8200
Email Addresses:
[email protected]
Total Funding:
217.35 M USD
Technology used in webpage:
SPF Google Maps Amazon Google Maps API GoDaddy DNS AWS Global Accelerator AppRiver
Similar Organizations
AltruBio
AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases.
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
Astria Therapeutics
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
Exelixis
Exelixis works is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-04-14 | Madrigal Pharmaceuticals | Madrigal Pharmaceuticals acquired by Synta Pharmaceuticals | 253.9 M USD |
Investors List
Galleon Group
Galleon Group investment in Series C - Synta Pharmaceuticals
Duquesne Capital Management
Duquesne Capital Management investment in Series C - Synta Pharmaceuticals
Mountain Trail Investments
Mountain Trail Investments investment in Series C - Synta Pharmaceuticals
SunAmerica
SunAmerica investment in Series C - Synta Pharmaceuticals
Caxton Associates
Caxton Associates investment in Series C - Synta Pharmaceuticals
Gollust Management
Gollust Management investment in Series C - Synta Pharmaceuticals
Official Site Inspections
http://www.syntapharma.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Synta Pharmaceuticals"
SyntalPharma - cleanroom and syntheses
High quality and good price in SyntalPharma, Poland. Menu. Homepage . About us . Our offer . Gallery . Contact . Contact data. Contact form. SyntalPharma - Your Reliable Partner in โฆSee details»
About us - SyntalPharma
The same rigour in Research, Development and Production employed in Syntal Chemicals, is applied in the approach of SyntalPharma, to its quality of R&D and associated products. Syntal Pharma has a dedicated 85m2, Class D, clean โฆSee details»
Synta Pharmaceuticals - Crunchbase Company Profile & Funding
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with โฆSee details»
Contact data - syntalpharma.com
Syntal Pharma Sp o.o. 44-121 Gliwice, ul. ลabฤdzka 59, Poland . www.syntalpharma.com. [email protected] . Phone: +48 32 270 82 36. Fax: +48 32 270 8241See details»
Syntalpharma Sp. z o.o. Company Profile - Poland - EMIS
Apr 27, 2024 SyntalPharma Sp Z O O is a company specializing in developing technology for the production of intermediates and active ingredients for pharmaceutical and cosmetic โฆSee details»
SyntalPharma - Overview, News & Competitors | ZoomInfo.com
SyntalPharma. Manufacturing · United States · <25 Employees. SyntalPharma Limited was established in 2015 as a Polish/Swiss venture. Our objective is to develop technology for the โฆSee details»
SYNTALPHARMA SP Z O O - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for SYNTALPHARMA SP Z O O of Gliwice, ลlฤ skie. Get the latest business insights from Dun & โฆSee details»
SyntalPharma - PharmaSource
SyntalPharma is a manufacturer that specializes in providing high-quality services to the pharmaceutical industry. Established in 1982, Syntal Chemicals operates from its โฆSee details»
Synta Pharmaceuticals - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial โฆSee details»
About SyntalPharma. - CPHI Online
Syntalpharma SP Zoo Offers A Wide Range Of Products Which Includes Orange Ii, 4-(20hydroxy-1-Naphthylazo) Benzenesulfonic Acid,Sodum Salt (C.I. 15510, Acid Orange 77). Contact Us โฆSee details»
Synta Pharmaceuticals CEO, Founder, Key Executive Team, Board โฆ
Synta Pharmaceuticals Management Team 10 Team Members. Synta Pharmaceuticals has 10 executives. Synta Pharmaceuticals's current Chief Executive Officer, President is Chen Schor.See details»
Synta and Madrigal Announce Merger Agreement to Create โฆ
Apr 14, 2016 Management and Organization Effective with the signing of the merger agreement, Dr. Friedman has stepped down from Syntaโs Board of Directors and will join Madrigal as an โฆSee details»
Synta Restructures Organization to Focus on New Priorities
Focus on advancing key programs to clinical proof of concept by 2010, without the need for additional capital. LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 13, 2009-- Synta โฆSee details»
Synta Pharmaceuticals Has Long-Term Potential - Seeking Alpha
May 10, 2012 Synta Pharmaceuticals (SNTA) is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical drugs for extending and โฆSee details»
SyntalPharma - cleanroom and syntheses
High quality and good price in SyntalPharma, Poland. Name and surname * E-mail * Subject I hereby give my consent to the processing of my personal data by SyntalPharma Sp. z o.o. โฆSee details»
Synta Pharmaceuticals Announces Closing of $75.3 million Round โฆ
LEXINGTON, Mass. - Synta Pharmaceuticals, an emerging pharmaceutical company, today announced the closing of a $75.3 million Round-B financing.See details»
Synta CEO bolts after less than a year, leaving a biotech on the mend
Apr 27, 2015 Synta Pharmaceuticals CEO Anne Whitaker is stepping down after just 9 months at the helm, heading back to Big Pharma as the company trims down and rallies around its โฆSee details»
Our offer - SyntalPharma
High quality and good price in SyntalPharma, Poland. Menu. Homepage . About us . Our offer . Gallery . Contact . Contact data. Contact form. Our offer . Custom synthesis with full GMP โฆSee details»
After PhIII failure Synta announces merger, shifts R&D focus
Apr 14, 2016 Things got worse in October when it terminated a Phase III trial of its second-line lung cancer candidate ganetespib, in use with chemotherapy, after analysis found it would do โฆSee details»
Working at Synta Pharmaceuticals - Glassdoor
Synta Pharmaceuticals doesn't fill stockings, but it might eventually fill the medical need of treating cancer. The drug development company has a handful of candidates in clinical and โฆSee details»